SCOTTSDALE, Ariz., Jan. 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published "Thought Leader Insight & Analysis: Obesity," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for obesity therapies.
By many measures, obesity in the Western World is reaching epidemic proportions. Unlike diabetes and cardiovascular disease, however, the medical justification for treating obesity is not directly tied to hard outcomes, and the pharmacoeconomics do not yet motivate third-party payers to broadly reimburse for pharmacotherapies.
Against this backdrop, seven internationally-recognized obesity experts
comment on centrally acting, peripheral and non-systemic approaches to
weight reduction, including:
-- Rimonabant, comparing next-generation CB-1 antagonists and inverse
agonists in terms of efficacy and propensity to cause depression and
other psychiatric disorders,
-- Other centrally acting agents, alone and in combination,
-- The pure peripheral drugs, using exenatide as the base for comparison
and positioning other GLP-1 agonists against its weaknesses,
-- Leptin, PYY, mitochondrial metabolism and other approaches to
"inefficient caloric consumption",
-- And non-systemic mechanisms, including follow up approaches after
orlistat, and novel approaches such as SGLT inhibition.
Key drugs discussed in this report include: Acomplia (rimonabant; Sanofi-Aventis), taranabant (MK-0364; Merck), CP-945598 (Pfizer), SLV 319 (BMS-646256; Solvay / BMS), rosonabant (E-6776; Esteve), AVE-1625 (Sanofi-Aventis), LH-21 (Instituto de Quimica Medica), Qnexa (phentermine / topiramate; Vivus), Contrave (bupropion / naltrexone; Orexigen), Empatic (bupropion SR + zonisamide SR; Orexigen), Meridia (sibutramine; Abbott), lorcaserin (APD356; Arena), Byetta (exenatide; Amylin/Lilly), exenatide LAR (Lilly/Amylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin; Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide + AC162352 (PYY 3-36; Amylin), liraglutide (NN2211; Novo Nordisk), albiglutide (GSK / Human Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-7871; UC Riverside / Chinese Academy of Science); Substituted quinoxalines (Novo Nordisk/ Pfizer), PYY 3-36 (Nastech), CYT009-GhrQb (Cytos), Xenical / alli (orlistat; Roche / GSK), cetilistat (Alizyme/ Takeda), SGLT inhibitors.
This report can be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
Copyright©2008 PR Newswire.
All rights reserved